Skip to Content

MedMira Inc MMIRF

Morningstar Rating
$0.09 +0.03 (46.10%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MMIRF is trading at a 353% premium.
Price
$0.09
Fair Value
$4.87
Uncertainty
Extreme
1-Star Price
$6.99
5-Star Price
$9.27
Economic Moat
Kfqc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MMIRF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.06
Day Range
$0.090.09
52-Week Range
$0.010.20
Bid/Ask
$0.03 / $0.30
Market Cap
$63.16 Mil
Volume/Avg
6,000 / 16,755

Key Statistics

Price/Earnings (Normalized)
Price/Sales
221.42
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees

Comparables

Valuation

Metric
MMIRF
DIA
AKYA
Price/Earnings (Normalized)
20.48
Price/Book Value
3.383.39
Price/Sales
221.424.881.13
Price/Cash Flow
16.24
Price/Earnings
MMIRF
DIA
AKYA

Financial Strength

Metric
MMIRF
DIA
AKYA
Quick Ratio
0.212.26
Current Ratio
0.223.07
Interest Coverage
−1.8611.71−6.68
Quick Ratio
MMIRF
DIA
AKYA

Profitability

Metric
MMIRF
DIA
AKYA
Return on Assets (Normalized)
−68.00%−32.09%
Return on Equity (Normalized)
11.76%−104.58%
Return on Invested Capital (Normalized)
10.85%−38.24%
Return on Assets
MMIRF
DIA
AKYA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
LkjdcxchRnfj$625.5 Bil
Vertex Pharmaceuticals Inc
VRTX
LftphshWwvypm$127.0 Bil
Regeneron Pharmaceuticals Inc
REGN
KymdymjtJfdzgqq$119.0 Bil
Moderna Inc
MRNA
ZnfnwwtqPtqn$47.1 Bil
Alnylam Pharmaceuticals Inc
ALNY
KsccpxqCfwcqy$33.0 Bil
argenx SE ADR
ARGX
FcmrqmvyNhwh$27.7 Bil
BioNTech SE ADR
BNTX
BzmlcyvnGjcw$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
HwsgqyxfcWthgnb$15.9 Bil
United Therapeutics Corp
UTHR
NwfprfrrCxp$14.4 Bil
Incyte Corp
INCY
DcdmdrvtkHpmjz$12.3 Bil

Sponsor Center